Adverse Events Seen With Combination Lenvatinib and Pembrolizumab for Recurrent Endometrial Cancer

Commentary
Video

Kimberly A. Spickes, CNP, details the adverse events she sees with combination lenvatinib and pembrolizumab treatment for recurrent endometrial cancer.

Related Videos
Gynecologic Cancers
© 2023 MJH Life Sciences

All rights reserved.